Coherus and J&J to Evaluate Combination Treatment for Prostate Cancer
ByAinvest
Wednesday, Feb 4, 2026 10:20 am ET1min read
CHRS--
JNJ--
Coherus Oncology has partnered with Johnson & Johnson to evaluate a combination treatment for metastatic castration-resistant prostate cancer. The partnership involves Coherus supplying its monoclonal antibody tagmokitug and Johnson & Johnson providing its bispecific antibody pasritamig. The two companies will sponsor a phase 1b trial to assess the efficacy and safety of the combination treatment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet